Collaboration to connect AstraZeneca's scientific and therapeutic expertise with Oracle's real-world data, cloud, AI, and clinical capabilities to accelerate clinical research and bring evidence-driven insights into care workflows to help improve patient care AUSTIN, Texas and ABU DHABI, UAE, Oct. 20, 2026 /PRNewswire/ -- Oracle today announced an agreement with AstraZeneca to explore how AI and real-world data can help clinicians identify eligible patients for clinical trials, accelerate evidence generation, and bring relevant research insights into everyday care.

The collaboration is expected to combine AstraZeneca's scientific and therapeutic expertise with Oracle's health data, cloud, AI, analytics, and clinical workflow capabilities.

Through a non-binding agreement, the companies plan to explore selected use cases that could improve clinical-trial efficiency and success by leveraging modern applications and AI to help care teams identify eligible patients earlier and easier, resulting in greater access to clinical trials for patients in need and helping to overcome one of the largest obstacles in clinical trials - patient recruitment.